Table 1 Patient demographics

From: Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study

 

Median (range)

Median age

37 (20-62)

Sex

 Male

18

 Female

14

Median interval from diagnosis to

8 (4−60)

HSCT, months(range)

Diagnosis

 De novo AML

22

 ALL

5

 MDS-EB II

3

 CMML

2

Disease status at transplantation

 CR1

12

 ≥CR2

2

 Primary refractory

7

 Secondary refractory

11

HCT-CI Median (range)

0 (0−1)

Conditioning regimens

 MAC

29

 RIC

3

Donor relationship with patients

 Sibling

7

 Parents

8

 Mother/father

 Offspring

15

 Cousin

2

  1. AML acute myelocytic leukemia, MDS-EB II myelodysplastic syndrome with excess blasts, type II, CMML chronic myelomonocytic leukemia, ALL acute lymphoblastic leukemia, CR complete remission, MAC myeloablative conditioning regimen, RIC reduced-intensity conditioning, HCT-CI Hematopoietic Cell Transplantation-Comorbidity Index [34]
Back to article page